Physician profile
Andrew E Yanofsky
NPI 1750549861
$2,547.94
in general payments reported to CMS, 2019-2025
27 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $305 · 2021: $205 · 2022: $379 · 2023: $547 · 2024: $250 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $610.11 | 2021-2025 | Dalvance, Avycaz, Teflaro |
| Viiv Healthcare Company | $403.39 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $320.01 | 2019-2022 | |
| Gilead Sciences, INC. | $250.96 | 2019-2025 | |
| Insmed, INC. | $172.34 | 2019-2025 | Arikayce |
| Allergan, INC. | $163.44 | 2019-2020 | |
| Organogenesis INC. | $96.57 | 2019-2021 | |
| Amgen INC. | $85.45 | 2020-2025 | Tavneos, Enbrel, Otezla |
| Janssen Biotech, INC. | $82.96 | 2019-2020 | |
| Pfizer INC. | $48.33 | 2022-2023 | |
| Paratek Pharmaceuticals, INC. | $45.62 | 2022-2023 | Nuzyra |
| Dexcom, INC. | $24.14 | 2024 | Dexcom G6 Transmitter |
| Harmony Biosciences LLC | $22.86 | 2023 | Wakix |
| Boston Scientific Corporation | $21.32 | 2023 | |
| Novo Nordisk INC | $19.92 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.12 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.61 | 2021 | |
| Amarin Pharma, INC. | $16.67 | 2019 | |
| Misonix INC | $16.20 | 2020 | |
| Sobi, INC | $15.94 | 2020 | |
| Hologic Sales and Service, LLC | $15.84 | 2025 | Aptima |
| Otsuka America Pharmaceutical, INC. | $14.63 | 2023 | Abilify Mycite |
| Ferring Pharmaceuticals INC. | $14.58 | 2022 | |
| Theratechnologies INC. | $13.70 | 2023 | Egrifta, Trogarzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.22 | 2021 | |
| Abbott Laboratories | $11.58 | 2019 | |
| Endo Pharmaceuticals INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Yanofsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.